Objective To assess the predictive value of Glasgow Prognostic Score ( GPS) system for mortality in patients with acute-on-chronic liver failure associated with hepatitis B ( HBV-ACLF) . Methods The clinical data of 437 patients who were diagnosed with HBV-ACLF and admitted to the Department of Infectious Diseases, The First Affiliated Hospital of Xinjiang Medical University, from April 2008 to April 2012 were retrospectively evaluated. Patients were grouped according to their GPS scores, and the mortality rates were compared between GPS groups. Continuous data in normal distribution were compared by t test between two groups and by F-test between three or more groups. Comparison of categorical data was made by chi-square test. COX proportional hazards regression was performed to identify clinical variables associated with overall survival during the follow-up period [30 ( 5-825) d]. Results The mortality rate of patients with HBV-ACLF was 68. 0% ( 297 cases) during the follow-up period. The group with higher GPS scores had significantly increased proportions of individuals with gastrointestinal bleeding, hepatic encephalopathy, and hepatorenal syndrome and higher Model of End-Stage Liver Disease scores ( P < 0. 05 across all variables) . COX proportional hazards regression analysis revealed the risk factors closely associated with the mortality of patients with HBV-ACLF, which included hepatic encephalopathy ( grade I-II vs absence of hepatic encephalopathy: hazard ratio, HR: 2. 520, 95% confidence interval, CI: 1. 479-4. 293, P = 0. 001; grade III-IV vs absence of hepatic encephalopathy: HR:3. 678, 95% CI: 1. 920-7. 047, P < 0. 001) , hepatorenal syndrome ( HR: 2. 374, 95% CI: 1. 452-3. 881, P = 0. 001) , gastrointestinal bleeding ( HR: 1. 616, 95% CI: 1. 153-2. 262, P = 0. 004) , antiviral therapy ( HR: 0. 668, 95% CI: 0. 518-0. 862, P = 0. 002) and the GPS ( 1 vs 0: HR: 2. 055, 95% CI: 1653-2. 702, P = 0. 001; 2 vs 0: HR: 4. 520, 95% CI: 3. 288-6. 932, P = 0. 007) . Conclusion The GPS system has a good predictive value for short-and long-term mortality in patients with HBV-ACLF. Elevated GPS is an independent risk factor for death in patients with chronic liver failure associated with hepatitis B.
[1]HE HL, LI JG, GAO ZL, et al.Investigation of artificial liver support system combined with stem cell transplantation in treatment of liver failure[J].J Clin Hepatol, 2013, 29 (9) :670-673. (in Chinese) 何宏亮, 李建国, 高志良, 等.人工肝和干细胞在肝衰竭治疗中的进展[J].临床肝胆病杂志, 2013, 29 (9) :670-673.
|
[2]KINOSHITA A, ONODA H, IMAI N, et al.The Glasgow Prognostic Score, an inflammation based prognostic score, predicts survival in patients with hepatocellular carcinoma[J].BMC Cancer, 2013, 13:52.
|
[3]PIERI G, AGARWAL B, BURROUGHS AK.C-reactive protein and bacterial infection in cirrhosis[J].Ann Gastroenterol, 2014, 27 (2) :113-120.
|
[4]SINGH PP, ZENG IS, SRINIVASA S, et al.Systematic review and meta-analysis of use of serum C-reactive protein levels to predict anastomotic leak after colorectal surgery[J].Br J Surg, 2014, 101 (4) :339-346.
|
[5]RIETZSCHEL de, DE BUYZERE M.High-sensitive C-reactive protein:universal prognostic and causative biomarker in heart disease?[J].Biomark Med, 2012, 6 (1) :19-34.
|
[6]MCMILLAN DC.An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer[J].Proc Nutr Soc, 2008, 67 (3) :257-262.
|
[7]MCMILLAN DC.The systemic inflammation-based Glasgow Prognostic Score:a decade of experience in patients with cancer[J].Cancer Treat Rev, 2013, 39 (5) :534-540.
|
[8]KAPTOGE S, SESHASAI SR, GAO P, et al.Inflammatory cytokines and risk of coronary heart disease:new prospective study and updated meta-analysis[J].Eur Heart J, 2014, 35 (9) :578-589.
|
[9]SILVESTRE JP, COELHO LM, PóVOA PM.Impact of fulminant hepatic failure in C-reactive protein?[J].J Crit Care, 2010, 25 (4) :657.e7-e12.
|
[10]CERVONI JP, THEVENOT T, WEIL D, et al.C-reactive protein predicts short-term mortality in patients with cirrhosis[J].J Hepatol, 2012, 56 (6) :1299-1304.
|
1. | 刘佳欣,郭晓俊,缪文华,杨红丽,闻正顺,郑斌,潘春飞,王艳玲. 罗非鱼皮胶原蛋白肽对高脂饮食小鼠肝脏氧化应激及肠道屏障的影响. 食品研究与开发. 2025(03): 55-61+86 . ![]() | |
2. | 王丹,惠登城,孙明瑜,武超. 中医药调节肠道菌群及代谢物治疗非酒精性脂肪性肝病的研究进展. 中西医结合肝病杂志. 2024(07): 646-651 . ![]() | |
3. | 曹鑫,党志博,李梦阁,刘晓慧,党中勤. 基于“肝脾相关”及“肠肝轴”理论探讨代谢相关性脂肪性肝病与肠道菌群的关系. 中西医结合肝病杂志. 2024(09): 846-850 . ![]() | |
4. | 马新蕾,周正,吴佩珊,肖菁菁,黎嘉辉. 基于“肠肝轴一菌群失调”探讨加味小柴胡汤治疗代谢相关脂肪性肝病的随机对照研究. 四川中医. 2024(12): 100-103 . ![]() | |
5. | 王曼菲,肖肽平,赵好好,马祺鑫,艾碧琛. 茵陈四苓汤对酒精性肝损伤大鼠肠黏膜屏障ZO-1及occludin的影响. 中医药导报. 2023(05): 31-35 . ![]() | |
6. | 张玉华,杜世奇,秦建增. 微生态制剂联合非诺贝特胶囊治疗非酒精性脂肪性肝病的疗效及对血清Visfatin、Apelin的影响. 江西医药. 2023(04): 460-463 . ![]() | |
7. | 廖小妹,陈美丽,张露,王玺舜,唐博翔,何文智. 基于肠肝轴探讨加味消脂利肝方调控肠道菌群治疗非酒精性脂肪肝病的作用机制. 中国微生态学杂志. 2023(08): 876-884 . ![]() | |
8. | 刘荣瑜,王昊,张子依,宋冬雪,陈锦瑞,汲晨锋. 多糖与肠道菌群相互作用的研究进展. 食品科学. 2022(05): 363-373 . ![]() | |
9. | 郑博文,王佳慧,罗淑娟,赵铁建,郭新华,郑洋. 肠道菌群丰度和多样性对肝纤维化的加速或延缓作用及特殊菌群的防治研究进展. 中国药理学与毒理学杂志. 2022(03): 217-224 . ![]() | |
10. | 安祯祥,李金芳,戴鸿志,何远利,王芳. 猕猴桃藤水提物对肝纤维化模型大鼠的保护作用及机制研究. 中药新药与临床药理. 2022(04): 426-432 . ![]() | |
11. | 李惠,王学红,马臻棋,马文霞,杨丽萍. 非酒精性脂肪性肝病患者粪便短链脂肪酸含量测定的临床意义. 临床肝胆病杂志. 2022(06): 1299-1306 . ![]() | |
12. | 刘淑慧,胡建华. 基于“肝-肠轴”理论探讨肠道微生物与肝衰竭的关系及治疗进展. 中西医结合肝病杂志. 2022(09): 854-856 . ![]() | |
13. | 柴焱,王亚妮,范引科,赵林涛,张小丽. 多因素诱导大鼠肝纤维化模型的建立及动态观察. 临床医学研究与实践. 2022(34): 1-4 . ![]() | |
14. | 谢佳秀,汤小军,陈红丽,钟路森,唐小玲,韦冬梅,黄建春. 相思藤醇提物对四氯化碳诱导肝纤维化大鼠的作用研究. 广西医科大学学报. 2021(05): 893-898 . ![]() | |
15. | 李洪海,李晓,马月香. 从“万物出乎震”谈肝气对肠道菌群的始动疏调作用. 时珍国医国药. 2021(05): 1176-1178 . ![]() | |
16. | 顾文. 茵陈蒿汤联合肠道益生菌治疗非酒精性脂肪性肝病的疗效探讨. 中国中西医结合消化杂志. 2021(10): 745-748 . ![]() | |
17. | 李文龙,廖宝春,曾祥泰. β-防御素2的生物学特性及与肠道相关疾病的关系. 赣南医学院学报. 2020(12): 1241-1246 . ![]() |